๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University201 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School89 Nanjing First Hospital, Nanjing Medical University68 The Second Hospital of Nanjing Medical University32 Nanjing Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanjing

1193 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
NCT06326736Pancreatic Cancer
Jinling Hospital, China
Phase EARLY_PHASE1
12
Nanjing
2024-04
Recruiting
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT06988956Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
95
Nanjing
2024-03-31
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543Esophagus Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Active, closed
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Salubris Biotherapeutics Inc
Phase 2
282
Changsha, Nanjing, Jining, Chengdu, Beijing, Chongqing
2024-03-28
Active, closed
A Study of Efficacy and Safety of TLL-018 in CSU Participants
NCT06396026Chronic Spontaneous Urticaria
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase 3
440
Nanjing
2024-03-27
Recruiting
Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia
NCT06725212Benign Prostatic Hyperplasia
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Recruiting
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT06222671Axial Spondyloarthritis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
180
Beijing, Chongqing, Zhengzhou, Nanjing, Shenzhen
2024-03-22
Recruiting
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
NCT06767813Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques
NCT06338293Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Phase 4
40
Nanjing
2024-03-15
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Active, closed
Research on Precision Pharmaceutical Care for Heart Transplant Recipients
NCT06326775Heart Transplant Patients
Nanjing First Hospital, Nanjing Medical University
Observational
500
Nanjing
2024-03-12
Recruiting
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
NCT06306456Non-Small Cell Lung Cancer With EGFR Mutation
Suzhou Genhouse Bio Co., Ltd.
Phase 1/2
94
Hefei, Zhengzhou, Changsha, Nanjing, Shanghai, Linhai
2024-03-05
Recruiting
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
NCT06285279Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy - PLA2R Induced, IgG4-Related Diseases
Nanjing University School of Medicine
Phase 1
24
Nanjing
2024-03-04
Recruiting
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)
NCT06283758Hypertension, Blood Pressure, Cardiovascular Diseases
Suzhou Municipal Hospital
Not applicable
30
Nanjing, Nantong, Suzhou
2024-03-01
By invitation
The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections
NCT06990126Clinical Efficacy and Safety
The First Affiliated Hospital with Nanjing Medical University
Observational
300
Nanjing
2024-03-01
Recruiting
Immunotherapy for Hepatocellular Carcinoma
NCT06241326Hepatocellular Carcinoma, Immunotherapy
The First Affiliated Hospital with Nanjing Medical University
Observational
11,000
Nanjing
2024-03-01
Recruiting
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
NCT06335836Social Isolation, SCD, Subjective Cognitive Decline, MCI
The First Affiliated Hospital with Nanjing Medical University
Observational
209
Nanjing
2024-03-01
Recruiting
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small MoleculeยฑSBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
NCT06662006Advanced Metastatic Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
56
Nanjing
2024-03-01
Recruiting
Washed Microbiota Transplantation for Type 1 Diabetes Mellitus
NCT06256614Type 1 Diabetes
The Second Hospital of Nanjing Medical University
Observational
50
Nanjing
2024-03-01
Recruiting
Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis
NCT06709092Allergic Rhinitis
Cheng Lei
Not applicable
60
Nanjing
2024-03-01
Recruiting
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05935215Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals
Phase 3
50
Nanjing, Beijing, Shanghai
2024-02-28
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
1,400
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Recruiting
Efficacy of Bioceramic Materials for Bone Defects Repair
NCT06249906Bone Lesion, Cartilage Degeneration, Osteo Arthritis Knee, Bone Fracture
Nanjing First Hospital, Nanjing Medical University
Not applicable
10
Nanjing
2024-02-20
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Beijing, Chongqing, Guangzhou, Nanjing, Shanghai, Chengdu, Jinhua
2024-02-19
Active, closed
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Not yet open
Corheart 6 LVAS Long-term Follow-up Study
NCT06267612Heart Failure
Nanjing First Hospital, Nanjing Medical University
Not applicable
30
Nanjing
2024-02-10
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
NCT06563869Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3
40
Nanjing
2024-02-02
Recruiting
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
NCT06198868Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Observational
60
Nanjing
2024-02-01
Recruiting
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
NCT06696742Bladder (Urothelial, Transitional Cell) Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
60
Nanjing
2024-02-01
Recruiting
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment
NCT07128394Infertility, Female, Luteinizing Hormone (LH)
Nanjing University
Not applicable
590
Nanjing
2024-02-01
Recruiting
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
NCT06694636Hepatocellular Carcinoma
Zhongda Hospital
Not applicable
5
Nanjing
2024-02-01
Recruiting
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
NCT06188624Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Recruiting
Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery
NCT06118034Inflammatory Response, Cardiac Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
768
Nanjing
2024-01-28
Recruiting
A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries
NCT07400406Coronary Artery Calcification
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2024-01-26
Recruiting
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B
NCT06525909Hepatitis B, Chronic
Tongji Hospital
Observational
250
Wuhan, Beijing, Changchun, Chongqing, Nanjing
2024-01-20
Recruiting
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
NCT06151262Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
30
Nanjing
2024-01-20
Recruiting
Neoadjuvant Therapy of HAIC๏ผˆGEMOX๏ผ‰ Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
NCT06208462Intrahepatic Cholangiocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
33
Nanjing, Chengdu, Ningbo
2024-01-19
Recruiting
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
NCT06220617Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma
Zhejiang University
Observational
3,600
Hangzhou, Guangzhou, Kunming, Nanjing, Xi'an, Zhengzhou
2024-01-11
Recruiting
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
NCT06192979Amyloidosis; Systemic, AL Amyloidosis
Jin Lu, MD
Not applicable
41
Beijing, Nanjing, Qingdao, Xiโ€™an
2024-01-05
Recruiting
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
NCT07065435HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
74
Nanjing
2024-01-01
Recruiting
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
NCT06254690Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
102
Nanjing
2024-01-01
Recruiting
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NCT06232694Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
54
Nanjing
2024-01-01
Recruiting
Development and Application of a Diagnosis and Treatment System for Children's Brain Diseases Based on Knowledge Graphs and Large Models
NCT06848959Cerebral Palsy, Mental Retardation, Tourette's Syndrome, Attention Deficit Hyperactivity Disorder
Yun Liu,PhD
Observational
2,000
Nanjing
2024-01-01
Recruiting
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
NCT07446452HER2-low Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
37
Nanjing
2024-01-01
Not yet open
Randomized Controlled Study of Optical 3D Navigated Repetitive Transcranial Magnetic Stimulation for Achalasia.
NCT06027190Esophageal Achalasia, Transcranial Magnetic Stimulation, Repetitive, Vagus Nerve Motor Disorder, Functional Magnetic Resonance Imaging
Zhang Nina
Not applicable
112
Nanjing
2024-01-01
Recruiting
CSP Versus BiVP for Heart Failure Patients With RVP Upgraded to Cardiac Resynchronization Therapy
NCT06241651Conduction System Pacing, Biventricular Pacing, Cardiac Resynchronization Therapy, Right Ventricular Pacing
The First Affiliated Hospital with Nanjing Medical University
Not applicable
66
Nanjing
2024-01-01
Recruiting
Prediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis (LVV) Based on PET/MRA Image Evaluation System
NCT06824714Large Vessel Vasculitis
Nanjing Medical University
Observational
150
Nanjing
2024-01-01
Recruiting
Establishing a Clinical Database and Biobank for Schizophrenia๏ผšA Cohort Study
NCT06123897Schizophrenia
Central South University
Observational
2,000
Hefei, Zhengzhou, Changsha, Nanjing
2024-01-01
Recruiting
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
NCT06669377Hepatocellular Carcinoma
Zhongda Hospital
Observational
444
Nanjing
2024-01-01
Recruiting
Clinical Efficacy and Population Pharmacokinetics of ฮฒ-lactams in Cirrhotic Patients
NCT07612163Bacterial Infections
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,000
Nanjing
2023-12-31
Active, closed
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasilยฎ9 in Young Women
NCT06197802Cervical Cancer, Condylomata Acuminata
Xiamen University
Observational
392
Nanjing
2023-12-30
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Nanjing
2023-12-27
Recruiting
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
NCT06081647Hypoxia, Gastric Polyp, Colon Cancer, Esophageal Cancer
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xiโ€™an, Tianjin, Hangzhou
2023-12-27
Recruiting
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
NCT06190665Hepatocellular Carcinoma
Zhongda Hospital
Not applicable
188
Beijing, Nanjing
2023-12-19
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
Washed Microbiota Transplantation for Malnutrition
NCT06447220Malnutrition
The Second Hospital of Nanjing Medical University
Observational
100
Nanjing
2023-12-17
Recruiting
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
NCT06255223Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor
Jinling Hospital, China
Phase 2
35
Nanjing
2023-12-15
Recruiting
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
NCT06177015Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 3
200
Nanjing
2023-12-11
Recruiting
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
NCT06354218Esophageal Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
50
Nanjing
2023-12-01
Recruiting
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
NCT05925452Active Systemic Juvenile Idiopathic Arthritis
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xiโ€™an, Chengdu
2023-12-01
Recruiting
Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis
NCT06162767Esophagogastric Junction Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
240
Nanjing
2023-12-01
Not yet open
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
NCT05965388HBV, HCC
Wen-hong Zhang
Observational
5,000
Hefei, Fuzhou, Wuhan, Nanjing, Xuzhou, Jinan, Taiyuan, Xiโ€™an
2023-12-01
Recruiting
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
NCT06051513Carbapenem-Resistant Enterobacteriaceae Infection
Southeast University, China
Not applicable
404
Hefei, Jinjiang, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Taizhou
2023-11-27
Recruiting
Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke
NCT06139692Acute Ischemic Stroke
Jinling Hospital, China
Phase 4
810
Nanjing, Chengdu
2023-11-21
Recruiting
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
NCT06341894Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
1,163
Nanjing
2023-11-17
Recruiting
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
NCT06091124Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
Active, closed
Effects of Dapagliflozin on Progression of Alport Syndrome
NCT06226896Alport Syndrome
Nanjing University School of Medicine
Observational
222
Nanjing
2023-11-15
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Recruiting
A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance Imaging for the Detection of Intracardiac Thrombus
NCT06146751Heart Aneurysm
The First Affiliated Hospital with Nanjing Medical University
Observational
320
Nanjing
2023-11-06
Recruiting
Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)
NCT06125925Atrial Fibrillation, HFpEF - Heart Failure With Preserved Ejection Fraction
The First Affiliated Hospital with Nanjing Medical University
Not applicable
436
Nanjing
2023-11-06
Recruiting
Real-world Evaluation of Qingxin Zishen Decoction on Ovarian Reserve Function Clinical Efficacy in Patients With Decreased
NCT06332742Decreased Ovarian Reserve
Yun Chen
Observational
178
Nanjing
2023-11-01
Active, closed
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610HER2-PositiveRecurrent or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
868
Nanjing
2023-11-01
Recruiting
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
NCT06001086Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
70
Nanjing
2023-11-01
Recruiting
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized๏ผŒOpen-label Clinical Trial.
NCT06079788Nephrotic Syndrome in Children
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Recruiting
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
NCT06182696Relapsed and/or Refractory Multiple Myeloma
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Not yet open
Study on the Safety and Effectiveness of the SnowyTM PFO Closure System
NCT05360771Patent Foramen Ovale
Hangzhou Dinova EP Technology Co., Ltd
Not applicable
242
Nanjing
2023-10-20
Recruiting
A Study of IBI363 in Subjects With Advanced Melanoma
NCT06081920Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan
2023-10-19
Recruiting
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
NCT06389760Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
57
Nanjing
2023-10-18
Recruiting
Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease
NCT06588231Coronary Heart Disease
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2023-10-17
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 3
306
Beijing, Shenzhen, Dongguan, Guangzhou, Changsha, Nanjing, Shanghai, Kunming
2023-10-03
Recruiting
Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer
NCT06360471Fertility Issues, Cancer
The First Affiliated Hospital with Nanjing Medical University
Observational
2,800
Nanjing
2023-10-01
Recruiting
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
NCT06058091Systemic Sclerosis
Jiangsu Renocell Biotech Company
Phase 1/2
81
Nanjing
2023-09-22
Recruiting
A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD
NCT06061627Heart Failure, Intraventricular Block
The First Affiliated Hospital with Nanjing Medical University
Not applicable
86
Nanjing
2023-09-21
Recruiting
WMT for Autism Spectrum Disorder (ASD)
NCT06030752Autism Spectrum Disorder
The Second Hospital of Nanjing Medical University
Observational
80
Nanjing
2023-09-20
Recruiting
Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion
NCT06542653Coronary Atheroscleroses
The First Affiliated Hospital with Nanjing Medical University
Observational
258
Nanjing
2023-09-17
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
GlaxoSmithKline
Phase 2/3
300
Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai
2023-09-13
By invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
argenx
Phase 3
240
Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou
2023-09-12
Recruiting
Omission of ALND in Breast Cancer Patients With Axillary pCR
NCT05939830Axillary Lymph Node Dissection, Pathological Complete Response, Neoadjuvant Systemic Therapy, Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
92
Nanjing
2023-09-11
Active, closed
Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth
NCT05698394Prenatal Depression, Ketamine, Postpartum Depression
Peking University First Hospital
Phase 4
364
Changsha, Nanjing, Hangzhou, Beijing
2023-09-09
Recruiting
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05860465Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
254
Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Wuhan, Nanjing
2023-09-08
Recruiting
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT06305832Prostate Cancer, Biochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
102
Nanjing
2023-09-07
Not yet open
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
NCT05730595Colorectal Neoplasms, Fluorescence, Lymph Node Excision
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
550
Hefei, Beijing, Chengdu, Fuzhou, Guangzhou, Shijiazhuang, Haerbin, Nanjing
2023-09-01
Not yet open
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT05976568Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3
668
Nanjing, Shanghai
2023-09-01
Active, closed
Therapeutic Effect of Stem Cell Eye Drops on Dry Eye Disease
NCT05784519Mesenchymal Stem Cell, Dry Eye Syndromes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase EARLY_PHASE1
10
Nanjing
2023-09-01
Recruiting
Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)
NCT06730334Psoriatic Arthritis, Secukinumab, Ultrasonography
Nanjing Medical University
Observational
400
Nanjing
2023-09-01
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Recruiting
Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients
NCT05974449Breast Cancer Female
The First Affiliated Hospital with Nanjing Medical University
Phase 2
60
Nanjing
2023-08-24
Rows per page Showing 801–900 of 1193
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing?page=9

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,193 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

713 of the 1,193 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 232 have not yet opened recruitment, 216 are active but closed to new participants, and 32 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.